Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

DDII UK Conference announces new panels on clinical trial design and early-stage funding

Published

on

""

The Drug Discovery Innovators & Investors (DDII) UK Conference will take place at etc.venues Monument, London, on Wednesday 4 November. The conference brings together R&D leaders, lab managers, decision-makers from pharma and biotech companies, industry suppliers, researchers, start-ups, and investors to discuss key challenges in UK drug development.

Two new panels have been confirmed for the day.

Get It Done: Designing Faster, More Effective UK Clinical Trials will examine how technology, policy and infrastructure are enabling better clinical trials in the UK. Panellists will discuss the current strengths, barriers and opportunities for companies conducting clinical trials in the UK. Speakers include Janet Hemingway (Professor, Liverpool School of Tropical Medicine) and Philippa Brown (Head of Development Operations, GSK), with additional speakers to be announced.

Where Is the Money? Funding Early-Stage UK Drug Development in a Difficult Market will take an honest look at where early-stage capital is actually flowing in the UK, and what founders can do when venture capital isn’t an option. The panel brings together Sam Goldsmith (Head of Venture Creation, Cell and Gene Therapy Catapult), Ayokunmi Ajetunmobi (Head of Ventures, Pioneer Group) and Tanya Moore (Investment Principal, Cancer Research Horizons’ Ventures team).

As announced previously, Chris Molloy, CEO of the UK BioIndustry Association, will deliver the conference keynote.

The full-day conference will also feature interactive breakout workshops on topics such as AI in drug discovery, lab automation, spatial biology, and cell and gene therapy.

The programme features structured networking breaks to facilitate meaningful connections. Through the conference app, attendees can review delegate profiles and schedule 1:1 meetings in advance. This approach helps you connect with investors, buyers, collaborators, or clinical trial partners from the start, maximising your time and minimising reliance on chance meetings.

Early bird registration rates are available until 30 September 2026.

Explore the Agenda Here

Register Now!

The post DDII UK Conference announces new panels on clinical trial design and early-stage funding appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read